奥麦罗制药（Omeros Corp）宣布，自2026年10月1日起，符合条件的医院将为Yartemlea药物获得额外的医疗保险（Medicare）报销。这一政策调整，旨在进一步支持医疗机构对该药物的临床应用。
奥麦罗制药（Omeros Corp）宣布，自2026年10月1日起，符合条件的医院将为Yartemlea药物获得额外的医疗保险（Medicare）报销。这一政策调整，旨在进一步支持医疗机构对该药物的临床应用。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.